IVEVF
What one share of Inventiva S.A. holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of MASH. We have a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
Inventiva S.A.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.03 |
|---|---|
| Profit | −$2.14 |
| Cash and investments | $0.60 |
| Debt | $0.36 |
| Book value | −$0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.18 | −$1.90 | — | −$1.97 | — | $3.44 |
| 2019 | $0.33 | −$1.44 | — | −$1.35 | — | $1.98 |
| 2020 | $0.01 | −$1.13 | — | −$1.03 | — | $3.52 |
| 2021 | $0.13 | −$1.50 | — | −$1.44 | — | $2.46 |
| 2022 | $0.31 | −$1.38 | — | −$1.14 | — | $1.15 |
| 2023 | $0.42 | −$2.63 | — | −$1.95 | — | −$0.68 |
| 2024 | $0.17 | −$3.33 | — | −$1.56 | — | −$1.15 |
| 2025 | $0.03 | −$2.14 | — | −$0.63 | — | −$0.17 |